Base de dados : MEDLINE
Pesquisa : E02.760.106 [Categoria DeCS]
Referências encontradas : 39096 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3910 ir para página                         

  1 / 39096 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29240910
[Au] Autor:Wehby GL; Domingue BW; Ullrich F; Wolinsky FD
[Ad] Endereço:Department of Health Management and Policy, University of Iowa, Iowa City.
[Ti] Título:Genetic Predisposition to Obesity and Medicare Expenditures.
[So] Source:J Gerontol A Biol Sci Med Sci;73(1):66-72, 2017 Dec 12.
[Is] ISSN:1758-535X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: The relationship between obesity and health expenditures is not well understood. We examined the relationship between genetic predisposition to obesity measured by a polygenic risk score for body mass index (BMI) and Medicare expenditures. Methods: Biennial interview data from the Health and Retirement Survey for a nationally representative sample of older adults enrolled in fee-for-service Medicare were obtained from 1991 through 2010 and linked to Medicare claims for the same period and to Genome-Wide Association Study (GWAS) data. The study included 6,628 Medicare beneficiaries who provided 68,627 complete person-year observations during the study period. Outcomes were total and service-specific Medicare expenditures and indicators for expenditures exceeding the 75th and 90th percentiles. The BMI polygenic risk score was derived from GWAS data. Regression models were used to examine how the BMI polygenic risk score was related to health expenditures adjusting for demographic factors and GWAS-derived ancestry. Results: Greater genetic predisposition to obesity was associated with higher Medicare expenditures. Specifically, a 1 SD increase in the BMI polygenic risk score was associated with a $805 (p < .001) increase in annual Medicare expenditures per person in 2010 dollars (~15% increase), a $370 (p < .001) increase in inpatient expenses, and a $246 (p < .001) increase in outpatient services. A 1 SD increase in the polygenic risk score was also related to increased likelihood of expenditures exceeding the 75th percentile by 18% (95% CI: 10%-28%) and the 90th percentile by 27% (95% CI: 15%-40%). Conclusion: Greater genetic predisposition to obesity is associated with higher Medicare expenditures.
[Mh] Termos MeSH primário: Índice de Massa Corporal
Predisposição Genética para Doença
Custos de Cuidados de Saúde/estatística & dados numéricos
Gastos em Saúde/estatística & dados numéricos
Medicare/estatística & dados numéricos
Herança Multifatorial/genética
Obesidade/genética
[Mh] Termos MeSH secundário: Idoso
Assistência Ambulatorial
Feminino
Seguimentos
Estudo de Associação Genômica Ampla
Seres Humanos
Masculino
Meia-Idade
Obesidade/economia
Obesidade/epidemiologia
Prevalência
Estudos Retrospectivos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.1093/gerona/glx062


  2 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468784
[Au] Autor:Kalbaugh CA; Kucharska-Newton A; Wruck L; Lund JL; Selvin E; Matsushita K; Bengtson LGS; Heiss G; Loehr L
[Ad] Endereço:Department of Surgery, School of Medicine, The University of North Carolina at Chapel Hill, NC corey_kalbaugh@med.unc.edu.
[Ti] Título:Peripheral Artery Disease Prevalence and Incidence Estimated From Both Outpatient and Inpatient Settings Among Medicare Fee-for-Service Beneficiaries in the Atherosclerosis Risk in Communities (ARIC) Study.
[So] Source:J Am Heart Assoc;6(5), 2017 May 03.
[Is] ISSN:2047-9980
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Outpatient ascertainment of peripheral artery disease (PAD) is rarely considered in the measurement of PAD clinical burden; therefore, the clinical burden of PAD likely has been underestimated while contributing to a decreased awareness of PAD in comparison to other circulatory system disorders. METHODS AND RESULTS: The purpose of this study was to estimate the age-standardized annual period prevalence and incidence of PAD in the outpatient and inpatient settings using data from the Atherosclerosis Risk in Communities (ARIC) study linked with Centers for Medicare and Medicaid Services claims. The majority (>70%) of all PAD encounters occurred in the outpatient setting. The weighted mean age-standardized prevalence and incidence of outpatient PAD was 11.8% (95% CI 11.5-12.1) and 22.4 per 1000 person-years (95% CI 20.8-24.0), respectively. Black patients had higher weighted mean age-standardized prevalence (15.6%; 95% CI 14.6-16.4) compared with white patients (11.4%; 95% CI 11.1-11.7). Black women had the highest weighted mean age-standardized prevalence (16.9%; 95% CI 16.0-17.8). Black patients also had a higher incidence rate of PAD (31.3 per 1000 person-years; 95% CI 27.3-35.4) compared with white patients (25.4 per 1000 person-years; 95% CI 23.5-27.3). PAD prevalence and incidence did not differ by sex alone. CONCLUSIONS: This study provides comprehensive estimates of PAD in the inpatient and outpatient settings where the majority of PAD burden was found. PAD is an important circulatory system disorder similar in prevalence to stroke and coronary heart disease.
[Mh] Termos MeSH primário: Assistência Ambulatorial
Planos de Pagamento por Serviço Prestado
Medicare
Admissão do Paciente
Doença Arterial Periférica/epidemiologia
[Mh] Termos MeSH secundário: Demandas Administrativas em Assistência à Saúde
Afroamericanos
Distribuição por Idade
Idoso
Assistência Ambulatorial/economia
Comorbidade
Grupo com Ancestrais do Continente Europeu
Planos de Pagamento por Serviço Prestado/economia
Feminino
Custos Hospitalares
Seres Humanos
Incidência
Masculino
Medicare/economia
Admissão do Paciente/economia
Doença Arterial Periférica/diagnóstico
Doença Arterial Periférica/economia
Doença Arterial Periférica/etnologia
Prevalência
Fatores de Risco
Distribuição por Sexo
Fatores de Tempo
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  3 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29226443
[Au] Autor:Ellenberg E; Taragin MI; Hoffman JR; Cohen O; Luft-Afik D; Bar-On Z; Ostfeld I
[Ad] Endereço:National Insurance Institute of Israel.
[Ti] Título:Lessons From Analyzing the Medical Costs of Civilian Terror Victims: Planning Resources Allocation for a New Era of Confrontations.
[So] Source:Milbank Q;95(4):783-800, 2017 12.
[Is] ISSN:1468-0009
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Policy Points: Across the globe, the threat from terrorist attacks is rising, which requires a careful assessment of long-term medical support. We found 3 major sources of costs: hospital expenditures, mental health services dedicated to acute stress reactions, and ambulatory follow-up. During the first year, most of the costs were related to hospitalization and support for stress relief. During the second year, ambulatory and rehabilitation costs continued to grow. Public health specialists should consider these major components of costs and their evolution over time to properly advise the medical and social authorities on allocating resources for the medical and nonmedical support of civilian casualties resulting from war or terror. CONTEXT: Across the globe, the threat from terrorist attacks is rising, which requires a careful assessment of long-term medical support. Based on an 18-month follow-up of the Israeli civilian population following the 2014 war in Gaza, we describe and analyze the medical costs associated with rocket attacks and review the demography of the victims who filed claims for disability compensation. We then propose practical lessons to help health care authorities prepare for future confrontations. METHOD: Using the National Insurance Institute of Israel's (NII) database, we conducted descriptive and comparative analyses using statistical tests (Fisher's Exact Test, chi-square test, and students' t-tests). The costs were updated until March 30, 2016, and are presented in US dollars. We included only civilian expenses in our analysis. FINDINGS: We identified 5,189 victims, 3,236 of whom presented with acute stress reactions during the conflict. Eighteen months after the conflict, the victims' total medical costs reached $4.4 million. The NII reimbursed $2,541,053 for associated medical costs and $1,921,792 for associated mental health costs. A total of 709 victims filed claims with the NII for further support, including rehabilitation, medical devices, and disability pensions. CONCLUSION: We found 3 major sources of costs: hospital expenditures, mental health services dedicated to acute stress reactions, and ambulatory follow-up. During the first year, most of the costs were related to hospitalization and support for stress relief. During the second year, ambulatory and rehabilitation costs continued to grow. Public health specialists should consider these major components of costs and their evolution over time to properly advise the medical and social authorities on allocating resources for the medical and nonmedical support of civilian casualties resulting from war or terror.
[Mh] Termos MeSH primário: Assistência Ambulatorial/economia
Vítimas de Crime/economia
Vítimas de Crime/estatística & dados numéricos
Custos de Cuidados de Saúde/estatística & dados numéricos
Hospitalização/economia
Serviços de Saúde Mental/economia
Centros de Reabilitação/economia
Terrorismo/economia
[Mh] Termos MeSH secundário: Assistência Ambulatorial/estatística & dados numéricos
Hospitalização/estatística & dados numéricos
Seres Humanos
Israel
Serviços de Saúde Mental/estatística & dados numéricos
Centros de Reabilitação/estatística & dados numéricos
Terrorismo/estatística & dados numéricos
Guerra
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1111/1468-0009.12299


  4 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29461349
[Au] Autor:Zolotorofe I; Fortini R; Hash P; Daniels A; Orsolini L; Mazzoccoli A; Gerardi T
[Ad] Endereço:Author Affiliations: Administrative Director Clinical Operations (Ms Zolotorofe) and Assistant Professor, Bon Secours Memorial College of Nursing (Ms Daniels), Medical Home, and Vice President and Chief Clinical Officer (Mr Fortini), Bon Secours Medical Group, Bon Secours Health System, Inc, Richmond, Virginia; Associate System Chief Nurse Executive (Dr Hash), Care Delivery and Advanced Practice Systems Consultant (Dr Orsolini), and Senior Vice President and Chief Nurse & Quality Officer (Dr Mazzoccoli), Bon Secours Health System, Inc, Marriottsville, Maryland; and Executive Director (Ms Gerardi), Tennessee Nurses Association, Nashville.
[Ti] Título:Return on Investment for the Baccalaureate-Prepared RN in Ambulatory Care.
[So] Source:J Nurs Adm;48(3):123-126, 2018 Mar.
[Is] ISSN:1539-0721
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Evidence supports the return on investment for an RN in ambulatory care. Utilizing RNs to their fullest potential in ambulatory practices is essential to effectively manage population health. Bon Secours Health System launched a new role, patient navigator RNs, to ensure seamless transitions of complex patients across care settings, resulting in better patient outcomes and a financial return.
[Mh] Termos MeSH primário: Assistência Ambulatorial/organização & administração
Bacharelado em Enfermagem/normas
Enfermeiras e Enfermeiros/normas
Navegação de Pacientes/normas
[Mh] Termos MeSH secundário: Assistência Ambulatorial/economia
Assistência Ambulatorial/recursos humanos
Análise Custo-Benefício
Seres Humanos
Enfermeiras e Enfermeiros/economia
Navegação de Pacientes/economia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM; N
[Da] Data de entrada para processamento:180221
[St] Status:MEDLINE
[do] DOI:10.1097/NNA.0000000000000586


  5 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384903
[Au] Autor:De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
[Ad] Endereço:Merck & Co., Inc., Kenilworth, NJ, USA.
[Ti] Título:Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
[So] Source:Medicine (Baltimore);96(52):e9163, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acute bacterial skin and skin structure infections (ABSSSI) are a frequent cause of hospital admissions in the United States. Safe and effective outpatient treatments may lower ABSSSI-associated health care costs by reducing unnecessary hospital admissions. Using data from 2 phase 3 trials (ESTABLISH-1, NCT01170221; ESTABLISH-2, NCT01421511), this post-hoc analysis explored the efficacy and safety of tedizolid in an outpatient setting. METHODS: Subgroup analysis was performed on US outpatients (defined as patients who were not in hospital at the time of treatment initiation) with ABSSSI caused by presumed or proven gram-positive pathogens. Patients were randomly assigned to receive tedizolid phosphate 200 mg once daily for 6 days (n = 403) or linezolid 600 mg twice daily for 10 days (n = 410). The primary end point was early clinical response (48-72 hours after the start of treatment). Secondary end points included investigator-assessed clinical response at end of therapy (EOT) and post-therapy evaluation (PTE; 7-14 days after therapy). Additional assessments included the patient-reported level of pain using a visual analog scale (VAS) and the per-pathogen favorable microbiological response rate at the PTE visit. Compliance with treatment and safety outcomes was also recorded. RESULTS: Early clinical response was similar between treatment groups (tedizolid, 82.4%; linezolid, 79.0%), as was investigator-assessed clinical response at EOT (tedizolid, 87.1%; linezolid, 86.1%) and PTE (tedizolid, 83.1%; linezolid, 83.7%). Mean changes from baseline to days 10 to 13 in VAS scores were identical between treatment groups (tedizolid, -51.9 mm; linezolid, -51.9 mm). Microbiological eradication rates were generally similar in both treatment groups for all key pathogens. Patients in both groups had favorable response at PTE. More tedizolid-treated patients (89.3%) than linezolid-treated patients (77.3%) were compliant with treatment. The most frequently reported drug-related treatment-emergent adverse events were nausea (tedizolid, 10.7%; linezolid, 13.8%), diarrhea (tedizolid, 4.5%; linezolid, 5.9%), and headache (tedizolid, 5.5%; linezolid, 4.4%). Treatment discontinuation rates were low for both treatment groups (tedizolid, 0.7%; linezolid, 1.0%). CONCLUSION: Short-course therapy with tedizolid can successfully treat patients with ABSSSI caused by presumed or proven gram-positive pathogens in an outpatient setting.
[Mh] Termos MeSH primário: Assistência Ambulatorial
Antibacterianos/uso terapêutico
Linezolida/uso terapêutico
Organofosfatos/uso terapêutico
Oxazóis/uso terapêutico
Dermatopatias Bacterianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Dermatopatias Bacterianas/patologia
Resultado do Tratamento
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Organophosphates); 0 (Oxazoles); ISQ9I6J12J (Linezolid); O7DRJ6R4DW (torezolid phosphate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009163


  6 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28462934
[Au] Autor:Ronca E; Scheel-Sailer A; Koch HG; Gemperli A; SwiSCI Study Group
[Ad] Endereço:Rehabilitation Services and Care Unit, Swiss Paraplegic Research, Nottwil, Switzerland.
[Ti] Título:Health care utilization in persons with spinal cord injury: part 2-determinants, geographic variation and comparison with the general population.
[So] Source:Spinal Cord;55(9):828-833, 2017 Sep.
[Is] ISSN:1476-5624
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:STUDY DESIGN: Cross-sectional survey. OBJECTIVES: To investigate annual rates and geographic variation of health care utilization in persons with spinal cord injury (SCI), and to identify factors associated with health care utilization. SETTING: Community setting, entire country of Switzerland. METHODS: Annual rates of planned and emergency visits to the general practitioner (GP), planned and emergency outpatient clinic visits and in-patient hospitalizations were compared between individuals with chronic SCI, over 16 years of age residing in Switzerland between late 2011 and early 2013 and a population sample (2012) of the Swiss general population. Risk factors for increased health service utilization were identified by means of regression models adjusted for spatial variation. RESULTS: Of 492 participants (86.2% response rate), 94.1% visited a health care provider in the preceding year, with most persons visiting GPs (88.4%) followed by outpatient clinics (53.1%) and in-patient hospitals (35.9%). The increase in utilization as compared with the general population was 1.3-, 4.0- and 2.9-fold for GP, outpatient clinic and in-patient hospital visit, respectively. GP utilization was highest in persons with low income (incidence rate ratio (IRR) 1.85) and old age (IRR 2.62). In the first 2 years post injury, health service visits were 1.7 (GP visits) to 5.8 times (emergency outpatient clinic visits) more likely compared with those later post injury. CONCLUSIONS: People with SCI more frequently use health services as compared with the general population, across all types of medical service institutions. GP services were used most often in areas where availability of specialized outpatient clinic services was low.
[Mh] Termos MeSH primário: Aceitação pelo Paciente de Cuidados de Saúde
Traumatismos da Medula Espinal/epidemiologia
Traumatismos da Medula Espinal/terapia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Assistência Ambulatorial/utilização
Doença Crônica
Estudos Transversais
Serviços Médicos de Emergência/utilização
Feminino
Geografia Médica
Hospitalização
Seres Humanos
Masculino
Meia-Idade
Análise de Regressão
Fatores de Risco
Suíça
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1038/sc.2017.38


  7 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28462932
[Au] Autor:Gemperli A; Ronca E; Scheel-Sailer A; Koch HG; Brach M; Trezzini B; SwiSCI Study Group
[Ad] Endereço:Rehabilitation Services and Care Unit, Swiss Paraplegic Research, Nottwil, Switzerland.
[Ti] Título:Health care utilization in persons with spinal cord injury: part 1-outpatient services.
[So] Source:Spinal Cord;55(9):823-827, 2017 Sep.
[Is] ISSN:1476-5624
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:STUDY DESIGN: This was a cross-sectional questionnaire survey. OBJECTIVES: The objective of this study was to identify the care-seeking behavior of persons with spinal cord injury (SCI) with respect to the various health care providers and ascertain circumstances that lead to situations where required care was not received. SETTING: This study was conducted in the entire country of Switzerland. METHODS: Statistical analysis of frequency of annual visits to health care providers by 17 specialties, and description of situations where health care was required but not received, in persons with chronic SCI living in the community. RESULTS: Main medical contact person was the general practitioner (GP; visited by 88% during last 12 months). The physiotherapist (visited by 72%) was the health care provider with the most visits (average of 30 visits in 12 months). GPs, physiotherapists, urologists and spinal medicine specialists were often contacted in combination, by many participants, often for check-up visits. A situation where care was required but not received was reported by 53 (11%) of participants, with a substantially higher rate in migrants (29%). Main problems why care was not received were bladder and bowel problems and main reasons of care not received were regional or temporal unavailability. CONCLUSIONS: Individuals with SCI are frequent users of medical services. There is no group of medical specialists that covers all needs of persons with SCI, what emphasizes health care provision from a comprehensive perspective including a wide array of services. Instances with care required but not received appeared to be rare and more likely in participants with migration background.
[Mh] Termos MeSH primário: Assistência Ambulatorial/utilização
Aceitação pelo Paciente de Cuidados de Saúde
Traumatismos da Medula Espinal/terapia
[Mh] Termos MeSH secundário: Doença Crônica
Terapias Complementares/utilização
Estudos Transversais
Feminino
Seres Humanos
Vida Independente
Masculino
Meia-Idade
Autorrelato
Traumatismos da Medula Espinal/epidemiologia
Suíça
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1038/sc.2017.44


  8 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456704
[Au] Autor:Schroeder CP; Van Anglen LJ; Dretler RH; Adams JS; Prokesch RC; Luu Q; Krinsky AH
[Ad] Endereço:Healix Infusion Therapy, Inc., 14140 Southwest Freeway, Suite 400, Sugar Land, TX 77478, USA.
[Ti] Título:Outpatient treatment of osteomyelitis with telavancin.
[So] Source:Int J Antimicrob Agents;50(1):93-96, 2017 Jul.
[Is] ISSN:1872-7913
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Telavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens including Staphylococcus aureus, the most frequent cause of osteomyelitis. Treatment is often challenging due to needs for surgical intervention along with prolonged administration of intravenous antimicrobials, frequently in an outpatient setting. This was a retrospective analysis of the efficacy and safety of telavancin for treatment of osteomyelitis provided as outpatient parenteral antimicrobial therapy (OPAT) in physician office infusion centres. Medical records of 60 patients receiving telavancin for osteomyelitis in 22 physician office infusion centres from 2010 to 2011 and 2013 to 2015 were reviewed. Of these, 60% were treated without hospitalisation, 37% had orthopaedic hardware and 56% had concurrent infections. Staphylococcus aureus was the most common pathogen (78%), primarily methicillin-resistant. The median duration of telavancin treatment in the outpatient setting was 21 days (range 3-105 days). Telavancin was used as first-line therapy in 32% of cases, following prior antibiotic failure in 47% and due to intolerance to previous agents in 22%, predominantly daptomycin or vancomycin. The telavancin dose was 10 mg/kg/day, adjusted for renal function in 25% of patients. The majority of patients self-administered telavancin at home via an elastomeric infusion pump. Overall clinical success was 73%. No significant differences in outcomes were observed with the presence of hardware, concurrent infection, concomitant therapies or type of osteomyelitis. Telavancin-associated adverse events occurred in 57%, with discontinuation in three patients (5%). These data demonstrate the effective and safe OPAT use of telavancin, providing an alternative for successful treatment of patients with osteomyelitis.
[Mh] Termos MeSH primário: Assistência Ambulatorial/métodos
Aminoglicosídeos/administração & dosagem
Antibacterianos/administração & dosagem
Infecções Bacterianas/tratamento farmacológico
Osteomielite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Aminoglicosídeos/efeitos adversos
Antibacterianos/efeitos adversos
Bactérias/classificação
Bactérias/isolamento & purificação
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Pacientes Ambulatoriais
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (Anti-Bacterial Agents); XK134822Z0 (telavancin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  9 / 39096 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29447145
[Au] Autor:Budd AP; Wentworth DE; Blanton L; Elal AIA; Alabi N; Barnes J; Brammer L; Burns E; Cummings CN; Davis T; Flannery B; Fry AM; Garg S; Garten R; Gubareva L; Jang Y; Kniss K; Kramer N; Lindstrom S; Mustaquim D; O'Halloran A; Olsen SJ; Sessions W; Taylor C; Xu X; Dugan VG; Katz J; Jernigan D
[Ad] Endereço:Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.
[Ti] Título:Update: Influenza Activity - United States, October 1, 2017-February 3, 2018.
[So] Source:MMWR Morb Mortal Wkly Rep;67(6):169-179, 2018 Feb 16.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Influenza activity in the United States began to increase in early November 2017 and rose sharply from December through February 3, 2018; elevated influenza activity is expected to continue for several more weeks. Influenza A viruses have been most commonly identified, with influenza A(H3N2) viruses predominating, but influenza A(H1N1)pdm09 and influenza B viruses were also reported. This report summarizes U.S. influenza activity* during October 1, 2017-February 3, 2018, and updates the previous summary (1).
[Mh] Termos MeSH primário: Vírus da Influenza A Subtipo H1N1/isolamento & purificação
Vírus da Influenza A Subtipo H3N2/isolamento & purificação
Vírus da Influenza B/isolamento & purificação
Influenza Humana/epidemiologia
Vigilância da População
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Assistência Ambulatorial/estatística & dados numéricos
Antivirais/farmacologia
Criança
Mortalidade da Criança
Pré-Escolar
Farmacorresistência Viral
Feminino
Hospitalização/estatística & dados numéricos
Seres Humanos
Lactente
Recém-Nascido
Vírus da Influenza A Subtipo H1N1/efeitos dos fármacos
Vírus da Influenza A Subtipo H1N1/genética
Vírus da Influenza A Subtipo H3N2/efeitos dos fármacos
Vírus da Influenza A Subtipo H3N2/genética
Vírus da Influenza B/efeitos dos fármacos
Vírus da Influenza B/genética
Influenza Humana/mortalidade
Influenza Humana/virologia
Masculino
Meia-Idade
Pneumonia/mortalidade
Gravidez
Estações do Ano
Estados Unidos/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180216
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6706a1


  10 / 39096 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241618
[Au] Autor:Agweyu A; Lilford RJ; English M; Clinical Information Network Author Group
[Ad] Endereço:Health Services Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya; Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: aagweyu@kemri-wellcome.org.
[Ti] Título:Appropriateness of clinical severity classification of new WHO childhood pneumonia guidance: a multi-hospital, retrospective, cohort study.
[So] Source:Lancet Glob Health;6(1):e74-e83, 2018 Jan.
[Is] ISSN:2214-109X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Management of pneumonia in many low-income and middle-income countries is based on WHO guidelines that classify children according to clinical signs that define thresholds of risk. We aimed to establish whether some children categorised as eligible for outpatient treatment might have a risk of death warranting their treatment in hospital. METHODS: We did a retrospective cohort study of children aged 2-59 months admitted to one of 14 hospitals in Kenya with pneumonia between March 1, 2014, and Feb 29, 2016, before revised WHO pneumonia guidelines were adopted in the country. We modelled associations with inpatient mortality using logistic regression and calculated absolute risks of mortality for presenting clinical features among children who would, as part of revised WHO pneumonia guidelines, be eligible for outpatient treatment (non-severe pneumonia). FINDINGS: We assessed 16 162 children who were admitted to hospital in this period. 832 (5%) of 16 031 children died. Among groups defined according to new WHO guidelines, 321 (3%) of 11 788 patients with non-severe pneumonia died compared with 488 (14%) of 3434 patients with severe pneumonia. Three characteristics were strongly associated with death of children retrospectively classified as having non-severe pneumonia: severe pallor (adjusted risk ratio 5·9, 95% CI 5·1-6·8), mild to moderate pallor (3·4, 3·0-3·8), and weight-for-age Z score (WAZ) less than -3 SD (3·8, 3·4-4·3). Additional factors that were independently associated with death were: WAZ less than -2 to -3 SD, age younger than 12 months, lower chest wall indrawing, respiratory rate of 70 breaths per min or more, female sex, admission to hospital in a malaria endemic region, moderate dehydration, and an axillary temperature of 39°C or more. INTERPRETATION: In settings of high mortality, WAZ less than -3 SD or any degree of pallor among children with non-severe pneumonia was associated with a clinically important risk of death. Our data suggest that admission to hospital should not be denied to children with these signs and we urge clinicians to consider these risk factors in addition to WHO criteria in their decision making. FUNDING: Wellcome Trust.
[Mh] Termos MeSH primário: Pneumonia/classificação
Pneumonia/terapia
Guias de Prática Clínica como Assunto
Índice de Gravidade de Doença
[Mh] Termos MeSH secundário: Assistência Ambulatorial
Pré-Escolar
Feminino
Hospitalização
Seres Humanos
Lactente
Quênia/epidemiologia
Masculino
Pneumonia/mortalidade
Estudos Retrospectivos
Medição de Risco/métodos
Resultado do Tratamento
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE



página 1 de 3910 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde